A multicenter open label Phase II study of the efficacy and safety of AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) as second line therapy in patients with recurrent platinum-sensitive ovarian cancer
ClinicalTrials.Gov
View All Studies